Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: Can we improve it?

Drug Resistance Updates

Volumn 4, Issue 3, 2001, Pages 152-167

  Jung, Laura L ^a,b   Zamboni, William C ^a,b,c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN; ALKALOID; ANTINEOPLASTIC AGENT; BN 80245; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DB 67; DIFLOMOTECAN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GYRASE INHIBITOR; HOMOCAMPTOTHECIN DERIVATIVE; HOMOSILATECAN DERIVATIVE; IRINOTECAN; KARENITECIN; LACTONE; PACLITAXEL; RUBITECAN; SILATECAN DERIVATIVE; TAXANE DERIVATIVE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; CANCER; CELL TRANSPORT; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFICACY; DRUG EXCRETION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; ENZYME ACTIVITY; HUMAN; MOLECULAR STABILITY; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0035187199     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.2001.0198     Document Type: Article

References (127)

1. Topoisomerase I inhibitors: Selectivity and cellular resistance
2. Antineoplastic agents from plants
3. Topoisomerase I interactive drugs in children with cancer
4. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site
5. Eukaryotic DNA topoisomerase I
6. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts
7. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children
8. Animal models for studying the action of topoisomerase I targeted drugs
9. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors
10. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro
11. A four-hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: Implications for treatment of children with metastatic medulloblastoma
12. Pharmacological determinants of 9-aminocampothecin cytotoxicity
13. Pharmacokinetic (PK) profile of 9-nitrocamptethecin (9-NC, RFS2000) following oral administration daily for 5 consecutive days every week
14. Phase I and pharmacokinetic (PK) study of intermittently administered 9-nitrocampothecin (9NC, Rubitecan) in patients with advanced malignancies
15. 7-Silylcamptothecins (silatecans): A new family of camptothecin antitumor agents
16. Novel A, B, E-ring modified camptothecins displaying high lipophilicity and markedly improved human blood stabilities
17. Plasma and cerebrospinal fluid pharmacokinetics of karenitecin (BNP-1350) in nonhuman primates
18. Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I targeted activity and antitumor properties
19. Homocamptothecin, an E-ring modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions
20. Clinical guidelines for managing topotecan-related hematologic toxicity
21. Phase I trial and pharmacokinetic (PK) and pharmacodynamic (PD) study of topotecan using a five-day course in children with refractory solid tumors: A pediatric oncology group study
22. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)
23. Alternative dosing schemes for irinotecan
24. A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer
25. A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer
26. In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells
27. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations
28. The intestinal absorption of camptothecin, a highly lipophilic drug, across Caco-2 cells is mediated by active transporter(s)
29. Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion
30. Reversal of MDR-I associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines
31. Overexpression of the BCRP/MXR/ABCP gene in a topotecan selected ovarian tumor cell line
32. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone and topotecan resistant cell lines
33. The HER tyrosine kinase inhibitor C11033 enhances cytotoxicity of 7-ehtyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux
34. P-glycoprotein reduces the oral availability of topotecan in mice
35. Does P-glycoprotein play a role in anticancer drug pharmacokinetics?
36. Clinical pharmacokinetics of probenecid
37. In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines
38. Antagonism between camptothecin and topoisomerase II directed chemotherapy agents in a human leukemia cell line
39. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cells lines
40. Low-level taxane exposure increases the activity of topoisomerase I targeted agents
41. Taxane effects on cell regulation and topoisomerase I activity
42. Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo
43. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts
44. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I
45. Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity
46. The current status of camptothecin analogues as antitumor agents
47. Camptothecins: From bench research to hospital wards
48. Plant antitumor agents. 25. Total synthesis and antileukemic activity of ring A substituted camptothecin analogues. Structure-activity correlations
49. Differential interactions of camptothecin lactone and carboxylate forms with human blood components
50. Marked interspecies variations concerning the interactions of camptothecin with serum albumin: A frequency-domain fluorescence spectroscopic study
51. Role of red blood cells in pharmacokinetics of chemotherapeutic agents
52. Topotecan in physiologic fluids: Depot of active drug in red blood cells
53. Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20-(S)-camptothecin in humans
54. Gender-dependent pharmacokinetics of topotecan in adult patients
55. Karenitecins: Further developments with BNP 1350, a novel, highly lipophilic, lactone stable camptothecin
56. Phase I trial of karenitecin administered intravenously daily for five consecutive days in patients with advanced solid tumors using accelerated dose titration
57. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo
58. Homocamptothecin, an E-ring modified camptothecin analogue, generates new topoisomerase I mediated DNA breaks
59. Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants
60. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma
61. Population pharmacokinetics of topotecan in children and adolescents
62. Topotecan reaction phenotype provides insight into topotecan drug interactions in patients
63. Topotecan is a cytochrome P-450 3A inhibitor: Clinical and pharmacological evidence
64. Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors
65. Hepatic biotransformation of docetaxel (Taxotere) in vitro: Involvement of the CYP3A subfamily in humans
66. Metabolism of docetaxel by human cytochromes P450: Interactions with paclitaxel and other antineoplastic drugs
67. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: Participation of cytochrome P-450 3A and drug interactions
68. Pharmacokinetics of irinotecan and metabolites in pediatric high-grade glioma patients with and without co-administration of enzyme-inducing anticonvulsants
69. The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms
70. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2
71. Proficient metabolism of irinotecan by a human intestinal carboxylesterase
72. Activation of CPT-11 in mice: Identification and analysis of a highly effective plasma esterase
73. The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase
74. Isolation and characterization of a cDNA encoding a horse liver butyrylcholinesterase. Evidence for CPT-11 drug activation
75. Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts
76. CPT-11 converting carboxylesterase and topoisomerase I activities in tumor and normal colon and liver tissues
77. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea
78. Comparison of mouse and human colon tumors with regard to phase I and phase II drug metabolizing enzyme systems
79. Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy
80. Use of the ornithine decarboxylase promoter to achieve N-MYC-mediated overexpression of a rabbit carboxylesterase to sensitize neuroblastoma cells to CPT-11
81. Genetic predisposition to the metabolism of irinotecan (CPT-11): Role of uridine diphosphate glucuronosyltransferase isoform IAI in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
82. Metabolism and pharmacokinetics of camptothecin analogue CPT-11 in the mouse
83. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGTIAI promoter polymorphism
84. Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: Prediction of biliary index and intestinal toxicity
85. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients
86. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital
87. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporine A
88. Antitumor activity of a camptothecin derivative CPT-11, against human tumor xenografts in nude mice
89. Effect of administration schedules on the antitumor activity of irinotecan, a camptothecin derivative
90. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts
91. Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts
92. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors
93. A phase I study of irinotecan in pediatric patients: A pediatric oncology group study
94. A phase I trial of 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum
95. Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan
96. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group study
97. Pharmacokinetically guided dose adjustment reduces variability in topotecan (TPT) systemic exposure in children with solid tumors
98. Pharmacokinetically guided use of topotecan (TPT) given (daily × 5) × 2, in children with solid tumors
99. Efficacy of treatment of colon, lung and breast human carcinoma xenografts with: Doxorubicin, cisplatin, irinotecan or topotecan
100. Efficacy and toxicity profile of oral topotecan in a panel of human tumor xenografts
101. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors
102. Bioavailability of and pharmacokinetics of oral topotecan: A new topoisomerase I inhibitor
103. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors
104. The evolving role of oral topotecan
105. Oral topoisomerase I inhibitors in adult patients: Present and future
106. Phase I and pharmacokinetic study of oral irinotecan in pediatric patients with solid tumors
107. Inter- and intrapatient variability in oral topotecan pharmacokinetics: Implications for body-surface area dosage regimens
108. A new oral dosage form of topotecan: Bioavailability and effect of food coadministration
109. Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan
110. A phase II study of rubitecan (RFS 2000, 9NC, 9-Nitro-20(S)-Camptothecin) in patients with refractory pancreatic cancer
111. Pharmacokinetic (PK) profile of 9-nitrocamptothecin (9-NC, RFS2000) following oral administration daily for 5 consecutive days every week
112. Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 9-nitro-20(S)-camptothecin as anticancer agents
113. Effect of food intake on the pharmacokinetics of a single administration of oral Rubitecan (RFS-2000), a topoisomerase-I-inhibiting camptothecin analogue
114. Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs, and mice
115. Plasma & urine disposition of 9-nitrocamptothecin (9NC, rubitecan) & its 9-aminocamptothecin (9AC) metabolite as part of a phase I study of intermittently administered rubitecan
116. New designs of clinical trials
117. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocyte leukemia. Identification of a relation between concentration and effect
118. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer
119. Escalating systemic exposure to topotecan following a 120 h continuous infusion in children with relapsed acute leukemia
120. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia
121. Defining the optimal dosage of methotrexate for childhood acute lymphoblastic leukemia. New insights from the lab and clinic
122. Individualized topotecan (TPT) dosing attains cytotoxic CSFTPT exposures in children with high-risk medulloblastoma
123. Increasing topotecan infusion from 30-minutes to 4 h infusions prolongs the duration of exposure in the cerebrospinal fluid
124. Topotecan: What dose, what schedule, what route?
125. Lactone stability of camptothecin in urine: Implications for the development of cystitis